Health
Radiopharmaceutical Shows Promise in Post-Pluvicto Setting
Abivax's radiopharmaceutical shows promise in treating post-Pluvicto conditions. The drug could offer new hope for patients dealing with ongoing health issues.
Coverage timeline — 1 article
STAT News
Abivax's ulcerative colitis data, Fulcrum's scrapped sickle cell drug, and more biotech news from The Readout
2026-06-02 15:04 UTC